Physician profile
David A Schomas
NPI 1811974199
$726.63
in general payments reported to CMS, 2019-2025
24 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $36.38 · 2021: $35.90 · 2022: $144 · 2023: $86.12 · 2024: $111 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $367 · Education: $23.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $367.19 |
| Education | $23.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $94.96 | 2019-2021 | |
| Genzyme Corporation | $73.22 | 2023-2025 | |
| Geron Corporation | $58.76 | 2025 | Rytelo |
| Acrotech Biopharma INC. | $53.21 | 2022 | |
| Incyte Corporation | $39.81 | 2024 | Monjuvi |
| Eisai INC. | $39.24 | 2022-2023 | |
| Lilly USA, LLC | $37.38 | 2022-2025 | Jaypirca, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $33.62 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $28.09 | 2025 | |
| Caris Mpi, INC. | $27.16 | 2025 | Mi Cancer Seek |
| Janssen Biotech, INC. | $25.21 | 2019-2024 | Carvykti |
| Sumitomo Pharma America, INC. | $23.93 | 2024 | Orgovyx |
| Merck Sharp & Dohme LLC | $21.64 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $20.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.76 | 2023 | Ultomiris |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $16.84 | 2024 | Krazati |
| Sobi, INC | $16.53 | 2024 | |
| Seagen INC. | $16.25 | 2023 | Adcetris |
| Varian Medical Systems, INC. | $15.88 | 2019 | |
| Siemens Medical Solutions USA, INC. | $15.54 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.19 | 2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $12.94 | 2021 | |
| Boston Scientific Corporation | $12.46 | 2019 | |
| Tactile Systems Technology INC | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.